Completed PHASE2 INTERVENTIONAL 1-arm NCT00299156

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)

Sponsor: Genzyme, a Sanofi Company

Conditions Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome

Interventions Clofarabine

Updated 6 times since 2017 Last updated: Oct 8, 2015 Started: Mar 31, 2006 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00299156, this PHASE2 trial focuses on Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome and remains completed. Sponsored by Genzyme, a Sanofi Company, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States